Management of oral mucositis at European transplantation centres.
Oral mucositis (OM), which occurs in many patients with hematologic malignancies treated with high-dose therapy and stem cell transplantation, is associated with substantial clinical, economic, and quality-of-life (QOL) consequences. It has been associated with an increased need for total parenteral nutrition and opioid analgesics, prolonged hospital stays, and increased risk of infection. The research subgroup of the European Group for Blood and Marrow Transplantation Nurses Group surveyed nurses at transplantation centres for their thoughts about the clinical, QOL, and economic consequences of OM; tools for assessing OM; strategies for preventing and treating OM; and the need for the development and implementation of treatment guidelines. The responses from 46 centres, in 16 countries, indicated that most nurses (91%) believe OM has a large effect on patients' QOL. Nurses are not highly satisfied with current treatments for OM, but they believe the discomfort is reduced with oral care protocols and mouthwashes. Oral mucositis is routinely and frequently assessed, however there are inconsistencies in how it is managed. Most centres used unpublished, centre-specific guidelines, and the survey found that most nurses agreed that published national guidelines would be valuable for standardising the assessment and management of OM.
Stone
Rebecca
R
Centre for Clinical Haematology, Nottingham University Hospitals NHS Trust, City Campus, Hucknall Road, Nottingham NG5 1PB, UK. rebecca.stone@nuh.nhs.uk
Potting
Carin M J
CM
Clare
Simon
S
Uhlenhopp
Mary
M
Davies
Michelle
M
Mank
Arno
A
Quinn
Barry
B
D005060:Europe; D051523:Fibroblast Growth Factor 7 / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D052016:Mucositis / Q000209:etiology* / Q000451:nursing*; D009730:Nursing Assessment; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D051523:Fibroblast Growth Factor 7